LAWRENCE COFFMAN: Open Payments
NPI 1275673980 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,091 in 38 payments from 9 companies in 2025. Trend: 2023 $64 · 2024 $694 · 2025 $1,091
Food & beverage: $1,023Education: $68
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 15 | $400 |
| Eisai Inc. | 5 | $143 |
| Janssen Biotech, Inc. | 7 | $138 |
| Boston Scientific Corporation | 1 | $135 |
| Sumitomo Pharma America, Inc. | 4 | $83 |
| Astellas Pharma US Inc | 3 | $72 |
| AstraZeneca Pharmaceuticals LP | 1 | $68 |
| Corcept Therapeutics | 1 | $29 |
| IMMUNITYBIO, INC. | 1 | $24 |
Products named: KEYTRUDA, Lenvima, ERLEADA, WATCHMAN FLX, LYNPARZA, ORGOVYX, Padcev, IMFINZI.
Industry payments across IN — which companies pay providers there.
